24 Common MDR Deficiencies - Orthopaedic Implants & Surgical Instruments

The intended purpose, indications, target population, anatomical site, intended users, clinical benefits, contraindications, warnings and procedural limits are not consistent.

This can happen across the IFU, labels, CER, SSCP, risk file, PMS/PMCF plan, GSPR checklist, implant card, patient information, surgical technique guide or marketing claims.

The file does not explain clearly enough why the product is a medical device, accessory, implantable device, surgical instrument, reusable instrument or part of a system.

The classification rationale may not fully address invasiveness, contact duration, implant status, sterility, reuse, measuring function, active features or the device’s role in the overall procedure.

Different sizes, models, materials, instruments, sterile configurations, generations or kit components are grouped together without enough explanation.

Notified bodies often question whether one evidence package can support all variants. The file should explain why the selected representative or worst-case configuration is appropriate, using technical, biological, clinical and manufacturing criteria.

The file does not clearly state which implants, instruments, accessories, trays, delivery systems, third-party components, imaging methods or ancillary devices are required, optional or compatible.

For orthopaedic systems, it should be clear how safety and performance are maintained when components are used together.

Raw materials, finished device materials, coatings, surface treatments, additives, colourants, processing aids, packaging materials and patient or user contacting components are not fully specified.

Common gaps include missing drawings, tolerances, surface finish requirements, supplier specifications, certificates, material grades or acceptance criteria.

Manufacturing flowcharts, site responsibilities, subcontractor activities, special processes, environmental controls, in-process checks, incoming inspection criteria and final release tests do not give enough detail.

The assessor needs to understand how the device is made, which sites are involved, which steps are critical and how conformity is maintained.

Critical outsourced activities are not clearly linked to supplier qualification, technical agreements, specifications, purchasing controls and change-control requirements.

This may include machining, moulding, coating, cleaning, packaging, sterilisation, laboratory testing, warehousing or design support.

The GSPR checklist lists standards or reports but does not explain applicability, non-applicability, partial applicability, the method used to demonstrate conformity or the exact controlled-document location of the evidence.

Broad references to whole reports often lead to further questions.

The submission relies on outdated standards, with drawn test methods, legacy assumptions or previous notified body acceptance without a current state of the art assessment.

Where older standards or alternative methods are used, the file should include a gap assessment and a clear technical rationale.

The risk management file does not clearly link hazards, foreseeable misuse, surgical workflow, residual risks, risk controls, verification of risk-control effectiveness, IFU warnings, usability evidence, clinical evaluation, PMS/PMCF data and benefit-risk conclusions.

In weaker files, risks are listed but do not shape the evidence strategy.

The file concludes that the benefit-risk profile is acceptable, but does not provide enough quantitative or clinically meaningful support.

For orthopaedic devices, the file should address complication rates, device deficiencies, revision or reoperation risks, residual risks, mechanical failure modes, adverse events, state of the art alternatives and the claimed clinical or procedural benefits.

Bench, laboratory, simulated-use or functional testing does not cover all relevant claims, indications, configurations or use conditions.

For orthopaedic implants and instruments, this may include fixation strength, insertion and removal, deployment, torque, pull-out, fatigue, wear, corrosion, particulate generation, cutting or drilling performance, handling, dimensional compatibility and procedure-specific performance.

For implants and instruments, common gaps include incomplete identification of contaminants, residues, particles, endotoxin, bioburden, cleaning agents, intermediate cleaning steps, final cleaning steps, method validation, sampling rationale, acceptance criteria, routine monitoring and revalidation triggers.

This matters especially where machining, moulding, polishing, coating or outsourced processing is involved.

Reports are included, but the file does not explain what was tested, why the method was suitable, whether deviations occurred, how acceptance criteria were selected, whether results support the GSPRs and whether the evidence applies to all marketed variants.

The biological evaluation does not fully consider contact type and duration, cumulative exposure, materials, processing residues, cleaning agents, packaging interaction, sterilisation effects, degradation, wear debris, extractables and leachables, target population, toxicological risk, evaluator competence or post-market biological safety signals.

The tested device, lot, size, geometry, material, surface finish, manufacturing route, sterilisation status, ageing condition, reprocessing cycle or packaging configuration is not clearly representative of the marketed device.

Notified bodies often challenge testing where the selected sample is not justified as the right worst case.

The submission does not adequately justify adoption into an existing sterilisation family or load configuration.

Common gaps include incomplete protocols or reports, missing raw data, weak product compatibility rationale, unclear SAL justification, insufficient bioburden strategy, inadequate EO residuals or radiation dose rationale, and poor linkage between sterilisation, packaging and shelf-life evidence.

The sterile barrier system is not clearly defined, or the file does not explain single versus double sterile barrier claims.

Deficiencies often relate to packaging specifications, seal parameters, OQ/PQ rationale, equipment equivalence, sample size, transportation simulation, accelerated ageing, real-time ageing, labelling durability and post-ageing sterile barrier integrity.

The file claims a shelf-life without enough evidence that mechanical performance, packaging integrity, sterility, biocompatibility, labelling readability, material properties and usability remain acceptable for the full claimed period.

The storage and transport conditions should also be defined.

Labels, IFU, surgical technique guides, implant cards, patient leaflets, SSCPs, training materials and promotional claims say different things.

Common gaps include missing target population, intended users, contraindications, residual risks, warnings, variant information, sterility status, single-use or reuse statements, MRI information where applicable, procedural limits and required accessories.

The file does not show that intended users can safely prepare, assemble, handle, implant, deliver, deploy, retrieve, clean, reprocess or dispose of the device.

Reliance on training, warnings or surgical technique instructions may be questioned if it is not supported by usability or human-factors evidence.

The CEP and CER do not clearly justify the level of clinical evidence needed for the device.

This is especially important for implantable devices, higher-risk devices, novel designs, devices with limited market history, devices relying on indirect clinical benefit, or instruments that enable a specific implant procedure.

Biological, technical and clinical equivalence may be asserted without enough detail, access to relevant technical data or comparison of differences.

Where differences exist, the file should explain why they do not affect clinical safety and performance. Similar-device benchmarking may also be incomplete or inconsistent with the state of the art and PMCF strategy.